ABOUT THIS STUDY
- Patients diagnosed with metastatic renal cell carcinoma and who will initiate sunitinib or pazopanib
- Enrolled on protocol 06-105, "Collection of specimens and clinical data from patients with renal cell carcinoma treated with targeted therapies," or receiving Pazopanib as part of routine clinical care.
- Found to have tumors that are 2.5cm or greater as determined by CT imaging
- Candidate lesions for ASL MRI should be 2.5cm or greater. Order of preference of lesion location will be as follows: abdominal lesions, bone lesions and chest lesions
- Contraindication to MRI
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New York, New York
- Toronto, Ontario
- Durham, North Carolina